HC Wainwright Forecasts Weaker Earnings for Cabaletta Bio

Key Points

• HC Wainwright trimmed its FY2030 EPS forecast for Cabaletta Bio to $0.87 from $0.89, while maintaining a Buy rating and a $16 price target.
• Analyst sentiment is mixed but leans positive: the stock has a Moderate Buy consensus rating and an average price target of $15.60. Recent ratings range from Strong Buy to Sell.
• Cabaletta Bio reported a quarterly loss of $0.28 per share, better than the $0.32 loss analysts expected; shares opened at $1.30 and recently traded near their one-year low of $1.18.

Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) - HC Wainwright decreased their FY2030 EPS estimates for shares of Cabaletta Bio in a report issued on Friday, November 6th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of $0.87 per share for the year, down from their prior estimate of $0.89. HC Wainwright currently has a "Buy" rating and a $16.00 target price on the stock. The consensus estimate for Cabaletta Bio's current full-year earnings is ($1.29) per share.

A number of other research analysts also recently weighed in on the company. Wells Fargo & Company reduced their target price on Cabaletta Bio from $4.00 to $3.00 and set an "equal weight" rating on the stock in a report on Friday, August 14th. TD Cowen upgraded Cabaletta Bio to a "strong-buy" rating in a research note on Monday, August 24th. William Blair upgraded Cabaletta Bio to a "strong-buy" rating in a research report on Wednesday, September 23rd. Wall Street Zen upgraded Cabaletta Bio from a "strong sell" rating to a "sell" rating in a research report on Saturday. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Cabaletta Bio in a research note on Thursday, October 15th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Cabaletta Bio presently has a consensus rating of "Moderate Buy" and an average price target of $15.60.

Cabaletta Bio Price Performance

Shares of CABA opened at $1.30 on Monday. Cabaletta Bio has a one year low of $1.18 and a one year high of $4.23. The company has a 50-day simple moving average of $2.12 and a two-hundred day simple moving average of $2.82. The firm has a market capitalization of $220.41 million, a PE ratio of -0.92 and a beta of 3.56.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.04.

Institutional Investors Weigh In On Cabaletta Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Opaleye Management Inc. increased its position in Cabaletta Bio by 180.0% during the 2nd quarter. Opaleye Management Inc. now owns 3,863,800 shares of the company's stock valued at $12,016,000 after buying an additional 2,483,800 shares in the last quarter. GSA Capital Partners LLP purchased a new position in Cabaletta Bio during the second quarter valued at $2,079,000. BlackRock Inc. purchased a new position in Cabaletta Bio during the second quarter valued at $33,447,000. Blue Owl Capital Holdings LP bought a new stake in Cabaletta Bio in the second quarter worth $2,223,000. Finally, Stonepine Capital Management LLC bought a new stake in Cabaletta Bio in the second quarter worth $2,852,181.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc is a clinical-stage biotechnology company focused on developing engineered T-cell therapies for patients with B cell-mediated autoimmune diseases. The company's approach is designed to selectively eliminate disease-causing immune cells and potentially provide durable disease remission rather than relying on continuous immunosuppression.

Its lead investigational product, CABA-201, is an autologous, fully human CD19 chimeric antigen receptor T-cell therapy designed to target and eliminate CD19-positive B cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.